Lowest Price Guaranteed From USD 4,499
Published
May 2019
Pages
323
View Count
24889
Example Insights
 |
 |
 |
 |
.PNG) |
 |
 |
.PNG) |
.PNG) |
Report Description
The global neoantigen targeted therapies market is likely to grow to $3 billion by 2030 at a CAGR of over 55%. Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, have severe detrimental effects on patients’ quality of life. Amongst the targeted anti-cancer therapies, immunotherapy has emerged as a potent option, capable of eliminating tumor cells with minimal side effects. For instance, the introduction of the immune check point inhibitors (such as PD-1/PD-L1 and CTLA-4 inhibitors) enabled healthcare providers to offer long term clinical benefit to patients suffering from metastatic tumors. However, these therapies have been reported to generate variable / inconsistent immune responses across different patients and, as a result, only a fraction of patients have actually ended up benefiting from such treatments. In fact, it is estimated that close to 70% of treated patients do not respond to single-agent immune checkpoint therapy.
Recent developments in genomic analysis and advances in bioinformatics have enabled the adoption of more personalized treatment approaches, such as neoantigen targeted therapies. Cancer neoantigens is a term used to refer to a subset of antigens encoded by tumor-specific, mutated genes, which have not previously been recognized by host’s immune system. These are considered to be potential biological targets that can be used to augment the therapeutic value of a number of cancer immunotherapies, including immune checkpoint inhibitors and cancer vaccines, having demonstrated the capability to elicit strong T-cell mediated immune response. Currently, several neoantigen-based therapies are being investigated in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab and nivolumab. In fact, multiple such initiatives by start-ups are backed by venture capital firms and other strategic investors.
The “Neoantigen Targeted Therapies Market, 2019-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others) [B] type of treatment (personalized and off-the-shelf), [C] type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy), [D] route of administration (intradermal, intravenous, subcutaneous, and others) and [E] key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for neoantigen targeted therapies, in the short-mid term and long term.
Chapter 3 provides a general overview of neoantigen targeted therapies, featuring brief descriptions of the various conventional forms of therapy that are used for the treatment of oncological disorders. It also includes a discussion on the advent and evolution of cancer immunotherapy, while highlighting its limitations. The chapter lays emphasis on the role of neoantigens in cancer immunotherapy, providing details on the various types of neoantigens, product development-related aspects of neoantigen targeted therapies and the diverse strategies that are available / being investigated for delivery of neoantigen-based therapeutics.
Chapter 4 includes information on nearly 150 molecules that are currently under development for the treatment of various cancer indications. It features a comprehensive analysis of pipeline molecules, highlighting phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.
Chapter 5 provides detailed profiles of some of the leading stakeholders in this field (shortlisted on the basis of number of pipeline products). Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent collaborations and an informed future outlook.
Chapter 6 provides a detailed analysis of close to 300 research articles related to neoantigen targeted therapies, published in the period 2015-2019 (till February). The analysis takes into consideration several aspects, namely target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period), within this domain.
Chapter 7 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to neoantigens. For this analysis, we looked at the patents that have been published by various players, till April 2019. The analysis highlights key details and trends associated with these patents, including patent type (granted patents, patent applications and others), publication year, patent issuing authorities / patent offices (USPTO, WIPO, APO, EPO and others), CPC classification, emerging focus areas and the leading industry / academic players. The chapter also includes a patent benchmarking analysis and a detailed valuation analysis.
Chapter 8 features an elaborate analysis and discussion on the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2014. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, distribution and supply agreements, service alliances and other agreements) that have been adopted by stakeholders in this domain. It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular therapies and disease indications.
Chapter 9 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till April 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.
Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of neoantigen targeted therapies till the year 2030. We have provided inputs on the likely distribution of the opportunity based on different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others), type of treatment (personalized and off-the-shelf), type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy), route of administration (intradermal, intravenous, subcutaneous, and others) and key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the neoantigen targeted therapies industry.
Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Gabriel Nistor (Chief Scientific Officer, AIVITA Biomedical), Ella Sorani (Vice President Research and Development, BioLineRx) and Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Immunotherapy
3.3. History of Cancer Immunotherapy
3.4. Limitations of Cancer Immunotherapy
3.5. Targeting Tumor-Specific Neoantigens
3.5.1. Types of Neoantigens
3.5.2. Role of Neoantigens in Cancer Immunotherapy
3.5.3. Neoantigen Targeted Therapies
3.5.3.1. Identification and Selection of Neoantigens
3.5.3.2. Delivery of Neoantigen Targeted Therapies
3.6. Key Challenges and Future Perspectives
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline
4.3. Neoantigen Targeted Therapies: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Immunotherapy
4.3.4. Analysis by Type of Therapy
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Type of Neoantigen
4.3.8. Analysis by Line of Therapy
4.3.9. Funnel Analysis: Analysis by Phase of Development, Type of Immunotherapy and Type of Therapy
4.3.10. Heptagon Representation: Analysis by Phase of Development and Route of Administration
4.4. Neoantigen Targeted Therapies: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developers
4.4.4. Analysis by Geography
4.5. Grid Analysis: Analysis by Target Disease Indication, Company Size and Location
5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES
5.1. Chapter Overview
5.2. Bavarian Nordic
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Neoantigen Targeted Therapies Portfolio
5.2.4. Recent Collaborations
5.2.5. Future Outlook
5.3. Genocea Biosciences
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Neoantigen Targeted Therapies Portfolio
5.3.4. Recent Collaborations
5.3.5. Future Outlook
5.4. Gradalis
5.4.1. Company Overview
5.4.2. Neoantigen Targeted Therapies Portfolio
5.4.3. Recent Collaborations
5.4.4. Future Outlook
5.5. Immunicum
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Neoantigen Targeted Therapies Portfolio
5.5.4. Recent Collaborations
5.5.5. Future Outlook
5.6. Immunovative Therapies
5.6.1. Company Overview
5.6.2. Neoantigen Targeted Therapies Portfolio
5.6.3. Recent Collaborations
5.6.4. Future Outlook
5.7. Iovance Biotherapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Neoantigen Targeted Therapies Portfolio
5.7.4. Recent Collaborations
5.7.5. Future Outlook
5.8. MediGene
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Neoantigen Targeted Therapies Portfolio
5.8.4. Recent Collaborations
5.8.5. Future Outlook
5.9. Neon Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Neoantigen Targeted Therapies Portfolio
5.9.4. Recent Collaborations
5.9.5. Future Outlook
6. PUBLICATION ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Neoantigen Targeted Therapies: List of Publications
6.3.1. Analysis by Year of Publication
6.3.2. Analysis by Type of Study
6.3.3. Analysis by Study Objective
6.3.4. Analysis by Affiliated Therapies
6.3.5. Analysis by Target Disease Indication
6.3.6. Key Journals: Analysis by Number of Publications
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Neoantigen Targeted Therapies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Geographical Location
7.3.3. Analysis by CPC Classifications
7.3.4. Analysis by Type of Industry
7.3.5. Emerging Focus Areas
7.3.6. Leading Players: Analysis by Number of Patents
7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Immunotherapy
8.3.4. Analysis by Type of Partnership and Type of Product
8.3.5. Analysis by Type of Partnership and Target Disease Indication
8.3.6. Regional Analysis
8.3.7. Most Active Players: Analysis by Number of Partnerships
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Therapies
9.3.5. Analysis by Amount Invested across Different Types of Indications
9.3.4. Analysis by Geography
9.3.5. Most Active Players: Analysis by Amount of Funding
9.3.6. Most Active Investors: Analysis by Number of Instances
9.4. Concluding Remarks
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1 Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Neoantigen Targeted Therapies Market, 2019-2030
10.3.1. Global Neoantigen Targeted Therapies Market: Distribution by Region, 2019-2030 (USD Million)
10.3.2. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.3.2.1. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
10.3.2.2. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030
10.3.2.3. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
10.3.2.4. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
10.3.2.5. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
10.3.2.6. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
10.3.2.7. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
10.3.2.8. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
10.3.3. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.3.3.1. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Targeted Therapies, 2019-2030 (USD Million)
10.3.3.2. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Targeted Therapies, 2019-2030 (USD Million)
10.3.4. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.3.4.1. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
10.3.4.2. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
10.3.4.3. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccines, 2019-2030 (USD Million)
10.3.4.4. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
10.3.5. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
10.3.5.1. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
10.3.5.2. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
10.3.5.3. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
10.3.5.4. Global Neoantigen Targeted Therapies Market for Other Routes of Administration, 2019-2030 (USD Million)
10.4. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
10.4.1. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.4.2. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
10.5. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
10.5.1. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.5.2. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.5.3. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.5.4. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
10.6. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
10.6.1. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.6.2. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.6.3. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.6.4. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
10.7. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
10.7.1. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.7.2. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.7.3. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.7.4. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
10.8. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)
10.8.1. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.8.2. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.8.3. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.8.4. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
10.9. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
10.9.1. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.9.2. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.9.3. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.9.4. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
10.10. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
10.10.1. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.10.2. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.10.3. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.10.4. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. AIVITA Biomedical
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Gabriel Nistor (Chief Scientific Officer)
12.3. BioLineRx
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ella Sorani (Vice President Research and Development)
12.3. VAXIMM
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Heinz Lubenau (Chief Operating Officer and Co-Founder)
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1. Global Age-Standardized Incidence Rates of Cancer in 2018 (per 100,000
Figure 3.2. Four Pillars of Cancer Therapy
Figure 3.3. Evolution of Cancer Immunotherapy
Figure 3.4. Limitations of Cancer Immunotherapy
Figure 3.5. Personalized and Off-the-shelf Neoantigens
Figure 3.6. Next Generation Sequencing of Neoantigens: Process Steps
Figure 4.1. Neoantigen Targeted Therapies: Distribution by Phase of Development
Figure 4.2. Neoantigen Targeted Therapies: Distribution by Type of Molecule
Figure 4.3. Neoantigen Targeted Therapies: Distribution by Type of Immunotherapy
Figure 4.4. Neoantigen Targeted Therapies: Distribution by Type of Therapy
Figure 4.5. Neoantigen Targeted Therapies: Distribution by Route of Administration
Figure 4.6. Neoantigen Targeted Therapies: Distribution by Target Disease Indication
Figure 4.7. Neoantigen Targeted Therapies: Distribution by Type of Neoantigen
Figure 4.8. Neoantigen Targeted Therapies: Distribution by Line of Therapy
Figure 4.9. Funnel Analysis: Distribution by Phase of Development, Type of Immunotherapy and Type of Therapy
Figure 4.10. Heptagon Representation: Distribution by Phase of Development and Route of Administration
Figure 4.11. Neoantigen Targeted Therapy: Distribution by Year of Establishment of Developer
Figure 4.12. Neoantigen Targeted Therapies: Distribution by Company Size and Geographical Location
Figure 4.13. Leading Developers: Distribution by Number of Therapies
Figure 4.14. Neoantigen Targeted Therapies: Distribution by Geographical Location of Developer
Figure 4.15. Grid Analysis: Distribution by Target Disease Indication, Company Size and Location
Figure 5.1. Bavarian Nordic: Annual Revenues, FY2014-FY2018 (DKK Million)
Figure 5.2. Medigene: Annual Revenues, FY2014-FY2018 (EUR Million)
Figure 6.1. Publications: Distribution by Year of Publication
Figure 6.2. Publications: Distribution by Type of Study
Figure 6.3. Publications: Distribution by Study Objective
Figure 6.4. Publications: Distribution by Affiliated Therapies
Figure 6.5. Publications: Distribution by Target Disease Indication
Figure 6.6. Key Journals: Distribution by Number of Publications
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Cumulative Distribution by Publication Year, Pre2010-2019
Figure 7.3. Patent Analysis: Distribution by Geographical Location
Figure 7.4. Patent Analysis: Distribution by Geographical Location, 2000-2009 and 2010-2019
Figure 7.5. Patent Analysis: Distribution by CPC Classification Symbols
Figure 7.6. Patent Analysis: Emerging Focus Areas
Figure 7.7. Patent Analysis: Distribution by Type of Applicant
Figure 7.8. Leading Industry Players: Distribution by Number of Patents
Figure 7.9. Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.10. Leading Individual Assignees: Distribution by Number of Patents
Figure 7.11. Patent Analysis: Benchmarking by Patent Characteristics
Figure 7.12. Patent Analysis: Distribution by Patent Age (January 2000 - April 2019)
Figure 7.13. Patent Analysis: Valuation Analysis
Figure 8.1. Partnerships and Collaborations: Cumulative Trend by Year, 2014-2019
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership, 2014-2016 and 2017-2019
Figure 8.4. Partnerships and Collaborations: Distribution by Type of Product
Figure 8.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Immunotherapy
Figure 8.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Target Disease Indication
Figure 8.7. Most Active Players: Distribution by Number of Partnerships
Figure 8.8. Partnership and Collaborations: Regional Distribution
Figure 8.9. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1. Distribution by Type of Funding and Year of Establishment of Company, 2014-2019
Figure 9.2. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2019
Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding and Year,
Figure 9.4. Funding and Investment Analysis: Cumulative Amount Invested, 2014-2019 (USD Million)
Figure 9.5. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2019
Figure 9.6. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2014-2019 (USD Million)
Figure 9.7. Funding and Investment Analysis: Summary of Investments, 2014-2019 (USD Million)
Figure 9.8. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Figure 9.9. Funding and Investment Analysis: Distribution by Amount Invested across Different Types of Indications
Figure 9.10. Funding and Investment Analysis: Distribution by Geography
Figure 9.11. Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.12. Most Active Investors: Distribution by Number of Instances
Figure 9.13. Funding and Investment Summary, 2014-2019 (USD Million)
Figure 10.1. Global Neoantigen Targeted Therapies Market, 2019-2030 (USD Million)
Figure 10.2. Global Neoantigen Targeted Therapies Market Distribution by Region, 2019-2030 (USD Million)
Figure 10.3. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.4. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
Figure 10.5. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 10.6. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
Figure 10.7. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
Figure 10.8. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
Figure 10.9. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
Figure 10.10. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
Figure 10.11. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
Figure 10.12. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.13. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Therapy, 2019-2030 (USD Million)
Figure 10.14. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Therapy, 2019-2030 (USD Million)
Figure 10.15. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.16. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
Figure 10.17. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
Figure 10.18. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccine, 2019-2030 (USD Million)
Figure 10.19. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
Figure 10.20. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.21. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
Figure 10.22. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
Figure 10.23. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
Figure 10.24. Global Neoantigen Targeted Therapies Market for Others Route of Administration, 2019-2030 (USD Million)
Figure 10.25. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
Figure 10.26. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.27. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.28. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.29. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.30. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
Figure 10.31. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.32. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.33. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.34. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.35. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
Figure 10.36. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.37. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.38. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.39. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.40. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
Figure 10.41. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.42. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.43. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.44. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.45. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)
Figure 10.46. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.47. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.48. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.49. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.50. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
Figure 10.51. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.52. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.53. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.54. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.55. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
Figure 10.56. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.57. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.58. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.59. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 3.1. Difference between Personalized and Off-the-shelf Neoantigens
Table 3.2. List of Neoantigen Targeted Combination Therapies
Table 3.3. List of Algorithms Used for Neoantigen Prediction
Table 3.4. Delivery Strategies for Neoantigen Therapies
Table 4.1. Neoantigen Targeted Therapies: Marketed and Development Pipeline
Table 4.2. Neoantigen Targeted Therapies: List of Companies
Table 5.1. Bavarian Nordic: Company Snapshot
Table 5.2. Drug Profile: CV301
Table 5.3. Drug Profile: BN-Brachyury
Table 5.4. Bavarian Nordic: Future Outlook
Table 5.5. Genocea Biosciences: Company Snapshot
Table 5.6. Drug Profile: GEN-009
Table 5.7. Genocea Biosciences: Future Outlook
Table 5.8. Genocea Biosciences: Company Snapshot
Table 5.9. Drug Profile: Vigil®
Table 5.10. Future Outlook
Table 5.11. Immunicum: Company Snapshot
Table 5.12. Drug Profile: Ilixadencel
Table 5.13. Immunicum: Future Outlook
Table 5.14. Immunovative Therapies: Company Snapshot
Table 5.15. Drug Profile: Chaperone Rich Cell Lysate
Table 5.16. Drug Profile: AlloStim®
Table 5.17. Drug Profile: AlloVax®
Table 5.18. Immunovative Therapies: Future Outlook
Table 5.19. Iovance Biotherapeutics: Company Snapshot
Table 5.20. Drug Profile: Lifileucel (LN-144)
Table 5.21. Drug Profile: LN-145
Table 5.22. Drug Profile: MDA TIL
Table 5.23. Iovance Biotherapeutics: Future Outlook
Table 5.24. MediGene: Company Snapshot
Table 5.25. Drug Profile: WT1 / PRAME
Table 5.26. Drug Profile: MDG1011
Table 5.27. MediGene: Future Outlook
Table 5.28. Neon Therapeutics: Company Snapshot
Table 5.29. Drug Profile: NEO-PV-01
Table 5.30. Drug Profile: NEO-PTC-01
Table 5.31. Drug Profile: NEO-SV-01
Table 5.32. Neon Therapeutics: Future Outlook
Table 6.1. Neoantigen Targeted Therapies: List of Publications, 2017-2018
Table 7.1. Patent Analysis: CPC Classification Symbol Definitions
Table 7.2. Patent Analysis: Popular CPC Classification Symbols
Table 7.3. Patent Analysis: List of Top CPC Classifications
Table 7.4. Patent Analysis: List of Leading Individual Assignees
Table 7.5. Patent Analysis: Benchmarking Analysis Summary
Table 7.6. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 8.1. Neoantigen Targeted Therapies: Partnerships and Collaborations, 2014-2019
Table 9.1. Neoantigen Targeted Therapies: Funding and Investments, 2014-2019
Table 13.1. Neoantigen Targeted Therapies: Distribution by Phase of Development
Table 13.2. Neoantigen Targeted Therapies: Distribution by Type of Molecule
Table 13.3. Neoantigen Targeted Therapies: Distribution by Type of Immunotherapy
Table 13.4. Neoantigen Targeted Therapies: Distribution by Type of Therapy
Table 13.5. Neoantigen Targeted Therapies: Distribution by Route of Administration
Table 13.6. Neoantigen Targeted Therapies: Distribution by Target Disease Indication
Table 13.7. Neoantigen Targeted Therapies: Distribution by Type of Neoantigen
Table 13.8. Neoantigen Targeted Therapies: Distribution by Line of Therapy
Table 13.9. Neoantigen Targeted Therapies: Distribution by Year of Establishment of Developer
Table 13.10. Neoantigen Targeted Therapies: Distribution by Company Size and Geographical Location
Table 13.11. Leading Developers: Distribution by Number of Therapies
Table 13.12. Neoantigen Targeted Therapies: Distribution by Geographical Location
Table 13.13. Bavarian Nordic: Annual Revenues, FY2014-FY2018 (DKK Million)
Table 13.14. MediGene: Annual Revenues, FY2014-FY2018 (EUR Million)
Table 13.15. Publications: Year of Publication
Table 13.16. Publications: Distribution by Type of Study
Table 13.17. Publications: Distribution by Study Objective
Table 13.18. Publications: Distribution by Affiliated Therapies
Table 13.19. Publications: Distribution by Target Disease Indication
Table 13.20. Key Journals: Distribution by Number of Publications
Table 13.21. Patent Analysis: Distribution by Type of Patent
Table 13.22. Patent Analysis: Cumulative Distribution by Publication Year, Pre2010-2019
Table 13.23. Patent Analysis: Distribution by Geographical Location
Table 13.24. Patent Analysis: Distribution by Geographical Location, 2000-200 9 and 2010-2019
Table 13.25. Patent Analysis: Distribution by Type of Applicant
Table 13.26. Leading Industry Players: Distribution by Number of Patents
Table 13.27. Leading Non-Industry Players: Distribution by Number of Patents
Table 13.28. Patent Analysis: Leading Individual Assignees
Table 13.29. Patent Analysis: Distribution by Patent Age (January 2000 - April 2019)
Table 13.30. Patent Analysis: Valuation Analysis
Table 13.31. Partnerships and Collaborations: Cumulative Trend by Year, 2014-2019
Table 13.32. Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.33. Partnerships and Collaborations: Distribution by Type of Partnership, 2014-2016 and 2017-2019
Table 13.34. Partnerships and Collaborations: Distribution by Type of Product
Table 13.35. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Immunotherapy
Table 13.36. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Target Disease Indication
Table 13.37. Most Active Players: Distribution by Number of Partnerships
Table 13.38. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 13.39. Funding and Investments: Distribution by Type of Funding and Year of Establishment, 2014-2019
Table 13.40. Funding and Investments: Cumulative Number of Instances by Year, 2014-2019
Table 13.41. Funding and Investments: Distribution by Type of Funding and Year, 2014-2019
Table 13.42. Funding and Investments: Cumulative Amount Invested, 2014-2019 (USD Million)
Table 13.43. Funding and Investments: Distribution of Instances by Type of Funding, 2014-2019
Table 13.44. Funding and Investments: Distribution of the Total Amount Invested by Type of Funding, 2014-2019 (USD Million)
Table 13.45. Funding and Investments: Summary of Investments, 2014-2019 (USD Million)
Table 13.46. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Table 13.47. Funding and Investments: Distribution by Amount Invested across Different Types of Indications
Table 13.48. Funding and Investments: Distribution by Geography
Table 13.49. Most Active Players: Distribution by Amount Invested (USD Million)
Table 13.50. Most Active Investors: Distribution by Number of Instances
Table 13.51. Funding and Investments Summary, 2014-2019 (USD Million)
Table 13.52. Global Neoantigen Targeted Therapies Market, 2019-2030 Base, Optimistic, Conservative Case (USD Billion)
Table 13.53. Global Neoantigen Targeted Therapies Market Distribution by Region, 2019-2030 (USD Million)
Table 13.54. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Table 13.55. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
Table 13.56. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030 (USD Million)
Table 13.57. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
Table 13.58. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
Table 13.59. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
Table 13.60. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
Table 13.61. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030
Table 13.62. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
Table 13.63. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.64. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Therapy, 2019-2030 (USD Million)
Table 13.65. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Therapy, 2019-2030 (USD Million)
Table 13.66. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.67. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
Table 13.68. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
Table 13.69. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccine, 2019-2030 (USD Million)
Table 13.70. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
Table 13.71. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.72. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
Table 13.73. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
Table 13.74. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
Table 13.75. Global Neoantigen Targeted Therapies Market for Others Route of Administration, 2019-2030 (USD Million)
Table 13.76. Neoantigen Targeted Therapies Market in the US, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.77. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.78. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.79. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.80. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.81. Neoantigen Targeted Therapies Market in the UK, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.82. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.83. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.84. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.85. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.86. Neoantigen Targeted Therapies Market in Germany, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.87. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.88. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.89. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.90. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.91. Neoantigen Targeted Therapies Market in France, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.92. Neoantigen Targeted Therapies Market in France: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.93. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.94. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.95. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.96. Neoantigen Targeted Therapies Market in Italy, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.97. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.98. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.99. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.100. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.101. Neoantigen Targeted Therapies Market in Spain, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.102. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Table 13.103. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.104. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.105. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.106. Neoantigen Targeted Therapies Market in Rest of the World, Base, Optimistic, Conservative Case, 2019-2030 (USD Million)
Table 13.107. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.108. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.109. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.110. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES